Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GLS | O94925 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 9/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GUSB | P08236 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25446872 | 0.91 | GLS (0.37) | GLSKDM4ETP53GBA1DRD2 | |
| SCHEMBL23945848 | 0.90 | GBA1 (0.44) | MAPTGLSGBA1ALDH1A1GUSB | |
| SCHEMBL23696408 | 0.83 | ADRB2 (0.40) | MAPTGLSGBA1 | |
| SCHEMBL16576128 | 0.83 | FNTA (0.36) | MAPTALDH1A1 | |
| SCHEMBL25564541 | 0.83 | KDM4E (0.35) | KDM4ETP53DRD2DRD4ALDH1A1 | |
| SCHEMBL25729664 | 0.81 | GLS (0.38) | MAPTGLSGBA1 | |
| SCHEMBL9889152 | 0.78 | MAPT (0.39) | MAPT | |
| SCHEMBL25587518 | 0.77 | ALDH1A1 (0.40) | GBA1ALDH1A1 | |
| SCHEMBL23635741 | 0.77 | HDAC1 (0.46) | — | |
| SCHEMBL20046976 | 0.75 | ALDH1A1 (0.52) | MAPTGLSKDM4ETP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364277-A1 | E-SELECTIN TARGETING AGENTS | GLYCOMIMETICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11548908-B2 | Heterobifunctional inhibitors of E-selectin and galectin-3 | GLYCOMIMETICS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220175808-A1 | GALACTOPYRANOSYL-CYCLOHEXYL DERIVATIVES AS E-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| US-11197877-B2 | Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists | GLYCOMIMETICS. INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200399301-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTIN AND GALECTIN-3 | GLYCOMIMETICS, INC. (US) | 2020-12-24 | — | — | US | disclosed |
| US-20200129536-A1 | GALACTOPYRANOSYL-CYCLOHEXYL DERIVATIVES AS E-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175808-A1 | GALACTOPYRANOSYL-CYCLOHEXYL DERIVATIVES AS E-SELECTIN ANTAGONISTS | SELE, SELPLG, SELP | MAPT 2975/4885GLS 667/4885KDM4E 4586/4885 |
| US-11197877-B2 | Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists | SELE, SELPLG, SELP | MAPT 2008/4885GLS 681/4885KDM4E 3860/4885 |
| US-20200399301-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTIN AND GALECTIN-3 | LGALS3, LGALS3BP, LGALS1 | MAPT 3430/4885GLS 592/4885KDM4E 4727/4885 |
| US-20230364277-A1 | E-SELECTIN TARGETING AGENTS | SELE, SELPLG, SELP | MAPT 2539/4885GLS 1573/4885KDM4E 4466/4885 |
| US-11548908-B2 | Heterobifunctional inhibitors of E-selectin and galectin-3 | LGALS3, LGALS3BP, LGALS1 | MAPT 3430/4885GLS 592/4885KDM4E 4727/4885 |
| US-20200129536-A1 | GALACTOPYRANOSYL-CYCLOHEXYL DERIVATIVES AS E-SELECTIN ANTAGONISTS | SELE, SELPLG, SELP | MAPT 2975/4885GLS 667/4885KDM4E 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.